Targeting mTOR-dependent tumours with specific inhibitors: A model for personalized medicine based on molecular diagnoses
Loading...
Citations
Altmetric:
Altmetric::
Download
Associated Records
Authors
File Licence
Editors
Date
2009-01-01
Source Title
Current Oncology
Journal Title
Journal ISSN
Volume Title
Publisher
MULTIMED INC
Melbourne Authors
Affiliation
Sir Peter MacCallum Department of Oncology
Document Type
Journal Article
Subject Code
Citation
Furic, L., Livingstone, M., Dowling, R. J. O. & Sonenberg, N. (2009). Targeting mTOR-dependent tumours with specific inhibitors: A model for personalized medicine based on molecular diagnoses. Current Oncology, 16 (1), pp.59-61. https://doi.org/10.3747/co.v16i1.406.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Cancer cells are characterized by aberrant growth arising from deregulated signalling pathways. The mammalian target of rapamycin (mTOR) pathway integrates multiple growth signals coming from both intracellular and extracellular cues. In this short review, we summarize what is known about the efficacy of targeting the mTOR pathway to treat cancer patients, and we explain the rationale behind promising new inhibitors that could show more potent tumour growth inhibition than did the first generation of these drugs.